

## Curriculum Vitae M.M. van den Heuvel-Eibrink

### Personalia

Name : Prof. dr. Marry M. van den Heuvel-Eibrink  
Male/Female : Female, married, 2 children, Floris (1994), Simone (1996)  
Date and place of birth : Doornspijk, 22-04-1960  
Address for correspondence : Dept. of Pediatric Oncology/Hematology, Princess Maxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands  
Telephone : +31-88 972 72 72  
Private address : Maarland NZ 27, 3231CE, Brielle  
E-mail : [m.m.vandenheuvel-eibrink@prinsesmaximacentrum.nl](mailto:m.m.vandenheuvel-eibrink@prinsesmaximacentrum.nl)  
BIG registration number : 39020832001  
BSN : 071381028  
AGB code (med. specialist) : 03046899

### Education and degrees

1987 MD, Faculty of Medicine, University of Utrecht, *cum laude*  
1987-1988 Internship in Internal Medicine/cardiology, (Lorenz Hospital, Zeist)  
1988-1994 Pediatric residency, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands including (prof. dr. H.K.A. Visser):  
a) 990-1991, 6 months Pediatric Oncology and Hematology training, Great Ormond Street hospital for Sick children, London (prof. dr. J. Chessels)  
b) 1993 One full year research training funded by the Dutch Cancer Society. Laboratory adult Hematology, Erasmus University (prof. dr. B. Lowenberg), Rotterdam  
1994-1997 Clinical fellowship pediatric Oncology and Hematology, Erasmus MC-Sophia Children's Hospital, and including visiting fellowship, St. Jude's Children's Research Hospital, Memphis (1995), TN, USA  
2001 PhD, Rotterdam, Erasmus MC-Sophia Children's Hospital, 04-07-2001. (Promotors: prof. dr. P. Sonneveld and prof. dr. R. Pieters). (Multidrug resistance studies in patients with AML)

### Positions

1997-1999 Chef de Clinique, Medical Coordinator department of pediatrics, Erasmus MC-Sophia Children's Hospital. (Fixed position department of pediatrics since 1998)  
1999-2005 Senior Staff member, department of pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital  
2008 Associate Professor of Pediatric Oncology (UHD), Erasmus MC-Sophia Children's Hospital, Rotterdam  
2009 Working group leader of the 'Erasmus MC Postgraduate Molecular Medicine School' which is recognized by the Dutch Royal Academy of Science and Arts (2 study groups, 1 on molecular unravelling of myeloid malignancies and 1 on (genetic) determinants toxicity during and after childhood cancer)  
2009 - 2015 Head of the "late effects after childhood cancer treatment" outpatient clinic EMC-Sophia, Rotterdam, the Netherlands  
2005 - 2015 Responsible for EMC-Sophia LATER research(PI), Rotterdam, the Netherlands  
2015 - onwards Senior consultant, Princess Maxima Centre, Utrecht, the Netherlands  
2015 - onwards Senior PI, translational research, Princess Máxima Center, Utrecht, the Netherlands  
2015 - 2019 Managing director establishing the LATER clinic, Princess Máxima Center, Utrecht, the Netherlands  
2018 -onwards Coordinator National Cancer in pregnancy(CIP)outpatient clinic for offspring in the Princess Maxima Centre

22-12-2023



2016 - onwards Professor in Translational Pediatric Oncology (renal tumors and toxicity), University of Utrecht, the Netherlands  
2018-onwards Coordinator international SIOP-RTSG office  
2022-onwards Chair SIOP-RTSG  
2023-onwards Member METC UMCU-NKI-PMC

### Other courses and training

- Postgrad course “Self-reflection and management”, 2000
- Skills in teaching “Teach the teacher”, Erasmus MC, 2008
- Female development career program 2007, selection by CV, and interviews
- Leadership programme (Management Development) Erasmus MC, 2010
- Training Course for Mentors for postdocs, Erasmus MC 2011
- BROK course for PIs in clinical research, accreditation 2013, updated 2016
- BROK course 2013, updated January 2016
- Financial management, Erasmus MC, November 2013 - January 2014
- BKO, June 2016

### Publications

See separate file attached

### (Inter)national Boards/Committees/Memberships

- Dutch Pediatric Association (NVK), since 1991 (member)
- Dutch Society of Oncology, NVvO, 1993- onwards (member)
- Dutch Hematology Association (NVvH), since 1995 (member)
- International Society of Pediatric Oncology (SIOP), since 1996 (member)
- European Hematology Association (EHA), since 1998 (member)
- American Society of Hematology (ASH), since 1998 (member)
- EWOG-MDS group 1999-onwards (member)
- Dutch Childhood Oncology Group (DCOG) Renal tumor committee 2000 - 2008 (member), 2009 - onwards (chair)
- I-BFM-AML committee, 2000-onwards (member)
- DCOG MDS protocol committee, 2003-onwards (chair)
- Scientific Board of EWOG MDS, 2005 - 2011 (member), 2011 - 2017 (chair)
- Steering committee DCOG-LATER committee, 2006 - onwards (member)
- Advisory Board of the International JMML Foundation, 2007- onwards (member)
- DCOG Disease Committee Bone Marrow Failure and MDS, 2008-onwards (member)
- SIOP Scientific Programs Advisory Committee (SPAC), 2008-2014 (contributor)
- DCOG Steering committee for Late effects, 2009- onwards (member)
- Steering CIE SIOP-RTSG, since 2009 (member), vice-chair since 2015
- Advisory Board of the DCOG (Raad van Toezicht), 2014 - onwards (member)
- Organizing committee of annual meeting of the European Hematology Association (EHA), SPC 2014, 2015, 2016 (member)
- Scientific EHA symposium board (SPC) 2014-2017 (member)
- SIOP scientific CIE, October 2017-2020 (member)
- Member SIOP-e (member)
- PanCare (member)

### Editorial Board

- European J of Cancer
- Journal of Pediatric Endocrinology

22-12-2023



### Reviewer

- Pediatric Blood and Cancer
- Haematologica
- J of Pediatric Biochemistry
- Clinical Cancer Research
- Leukaemia Research
- J Ped Hem Onc
- Clin Cancer Research
- Leukaemia
- British J of Hematology
- J of supportive care in Cancer
- European J of Endocrinology
- Cancer
- Am J of Blood
- Eur J of Cancer
- Lancet Oncology
- BMC
- JCO
- Cancers

### Research summary

Over the past years I have developed 2 research lines:

- a) Clinical Research on outcome, (genetic) determinants of quality of care and cure, direct and late toxicity

This research group focusses on improvement of quality of care and cure, on avoidance and/or reduction of toxicity during and after treatment and to identify determinants including genetic variation in and molecular determinants of adverse effects. This is increasingly important as 75% of the children with cancer are cured. In the recent years, we have focussed on endocrine side effects of treatment in children with cancer. Ongoing and future studies are done in close collaboration with other late effects clinics in the Netherlands organised by the DCOG funded by a Quality of Life grant which established a solid financial basis for this national late effects research network. In 2013 I obtained a EU FP7 research grant for studying genetic variation in genetic and audiological toxicity in childhood cancer survivors.

- b) Translational laboratory research

- Childhood myeloid malignancies (“AML/MDS”)(Laboratory of Pediatric Onc/Hem.)(Chaired together with Dr C.M. Zwaan).This research detected biological determinants of leukemogenesis and treatment outcome, and to develop targeted therapies for pediatric AML/MDS”. This work was performed in close connection to the chairmanship of the Scientific Committee of the international EWOG MDS Group, and active membership of the international IBFM-AML Group. Accrual of survivors for research was enhanced by grants by Kika and ODAS. I have build off this amyloid malignancy program over the past 6 years, to be able to further focus on pediatric renal tumors.
- Pediatric renal tumors I am chair of the International Steering committee for pediatric renal tumors of the SIOP-RTSG and chair of the National DCOG-renal tumour Group. I supervise(d) 14 translational PhD projects on renal tumors in children and I am co-PI and coordinator of initiation and data collection, in the international task force to lead on the SIOP-RTSG UMBRELLA 2016 care and research initiative, which aims to include >3000 pediatric renal tumour patients in Europe. In the Prinses Máxima Centrum I started the translational renal tumor program, including clinical (RT, radiology, pathology outcome) research as well as translational laboratory research,

22-12-2023



clinical genetics, (NGS) and organoid development to create models to indentify targets for novel therapy development.

Currently, in total I am responsible for 2 post-docs, 21 PhD students(+ 38 already finished/approved theses projects), 1 research physician, 2 data managers, 2 trial managers.

**(Co)promotor/Thesis supervisor past projects:**

1. March 17, 2010. R.D. van Beek. "Endocrine effects of the Treatment for acute Lymphoblastic Leukemia and Hodgkin's Lymphoma", Erasmus MC, Rotterdam (Promotor R. Pieters).
2. May 25, 2011. B. Balgobind. "Unraveling pediatric MLL-rearranged Acute Myeloid Leukaemia", Erasmus MC, Rotterdam. (Promotor R. Pieters).
3. November 16, 2011. I. Hollink. "Molecular aberrations in cytogenetically normal pediatric AML". Erasmus MC, Rotterdam (Promotor R. Pieters).
4. September 19, 2012, M. van Waas. "Metabolic syndrome in childhood cancer survivors" Erasmus MC, Rotterdam (Promotor R. Pieters).
5. November 21, 2012, A.C.H. de Vries (Molecular aberations in MDS/JMML), Erasmus MC, Rotterdam (Promotor R. Pieters).
6. June 26, 2013, E.A. Coenen, Molecular and genetic aberrations of *MLL*-rearranged pediatric AML, Erasmus MC, Rotterdam (Promotor R. Pieters).
7. September 4, 2013, M. L. te Winkel, Osteogenic toxicity in childhood ALL, Erasmus MC, Rotterdam.(Promotor R. Pieters).
8. September 11, 2013, K. Blijdorp, Determinants and sequelae of body composition in adult childhood cancer survivors, Erasmus MC, Rotterdam.(Promotor A.J. van der Lely).
9. September 12, 2013, H. Segers, Wilms tumors: genotypes and phenotypes, Erasmus MC Rotterdam. (Promotor R. Pieters)
10. November 6, 2013, M. Blink, Molecular characterisation of DS-AML. Erasmus MC, Rotterdam. (Promotor R. Pieters).
11. April 16, 2014, W. van Dorp, Gonadal damage during and after childhood cancer treatment. Erasmus MC, Rotterdam (Promotors J. Laven, R. Pieters).
12. May 13, 2014, A. Aalbers, Bonemarrow failure and MDS in children). Erasmus MC, Rotterdam (Promotor R. Pieters).
13. July 2, 2014, T Buitenkamp. Molecular characterisation of DS-ALL. Erasmus MC, Rotterdam (Promotor R. Pieters).
14. June 17, 2015, J. E. Kuipers. Epigenetic deregulation in pediatric AML. Erasmus MC, Rotterdam (Promotor R. Pieters).
15. June 15, 2016, J. de Rooij, Molecular unravelment of AML M7 (Promotor CM Zwaan and R. Pieters).
16. November 6, 2016, L. Warris, Restoring the balance, Dexamethasone toxicity in children with ALL (Promotors R. Pieters and M.M. van den Heuvel-Eibrink)
17. May 13, 2017 M den Hoed, bone toxicity, the flipside of treatment (Promotors R. Pieters and M.M. van den Heuvel-Eibrink).
18. May 31, 2017, S. Gooskens. CCSK in children (Promotors R. Pieters and M.M. van den Heuvel-Eibrink).
19. September 12, 2017. I.M.M. van der Geest. Perspectives on palliative care in children with cancer, UU Utrecht(Promotors R. Pieters and M.M. van den Heuvel-Eibrink)
20. April 6, 2018, M. Wijnen, Endocrine and metabolic sequelae of tumors with a focus on craniopharyngioma, Rotterdam (Promotors A.J. van der Lelij and M.M. van den Heuvel-Eibrink)
21. March 19, 2019 E. Clemens, Clinical and genetic determinants of ototoxicity during and *after* childhood cancer, UU Utrecht (Promotor M.M. van den Heuvel-Eibrink)

22-12-2023



22. October 8, 2019 N. van Oosterom, (Epigenetic) and biological determinants of methotrexate induce Mucositis in children with ALL UU Utrecht (Promotors M.M. van den Heuvel-Eibrink and R. Pieters)
23. October 30, 2019. A.L. van der Kooij, gonadal late effects during and after childhood cancer. Rotterdam (Promotors Prof J.S.E. Laven and M.M. van den Heuvel-Eibrink)
24. November 12th 2019. A. Ooms, Wilms Tumor: towards integration of histopathological and genomic characteristics”, UU Utrecht (Promotors: M.M. van den Heuvel-Eibrink and co-promotor R.R. de Krijger and J. Drost).
25. March 23, 2020. Boon, B, “Playscapes: Creating Space for Young Children’s Physical Activity and Play”, Technical University, Delft (Promotors; P.J. Stappers and M.M. van den Heuvel-Eibrink, co-promotor M.C. Rozendaal).
26. September 30, 2021, A.J. M. Meier: “Childhood related hearing loss and tinnitus”, UU Utrecht.(Promotors: M.M. van den Heuvel-Eibrink and co-promotors: A.E. Hoetink, and M. van Grotel).
27. December 15, 2021, S.S. van Santen: “Body transformation in Life after Tumor:Long term consequences for endocrinology, metabolism, and bone. Erasmus University, Rotterdam. (Promotors: A.J. van der Lely, and M.M. van den Heuvel-Eibrink, co-promotor: S.J.C.M.M. Neggers)
28. February 17, 2022, J.Mul. Highly convocal flank irradiation using new flank target volumes in pediatric renal tumors, UU Utrecht. (Promotor: M.M. van den Heuvel-Eibrink, co-promotors”G.O.R Janssens, M.van Grotel)
29. March 17, 2022, J.Hol. Renal tumors in children, and the role of (epi)genetic predisposition. UU Utrecht. (Promotor: M. M. van den Heuvel-Eibrink, co-promotors: R.Kuipers, M.Jongmans.
30. November 9, 2022. S Noort, Unraveling pediatric AML. Erasmus University, Rotterdam. (Promotors: C.M. Zwaan, M.M. van den Heuvel-Eibrink, co-promotor: M.Fornerod).
31. November 10, 2022. R. Faradja Davilla, Towards refining RT in children with Wilms tumor. UU Utrecht.Promotors: M.M. van den Heuvel-Eibrink, C.Terhaard, Co-promotors: G.O.R. Janssens, M. van Grotel)
32. November 25, 2022. C. Calandrini. Applying Organoid technology to pediatric cancer research. UU Utrecht (Promotors: H. Clevers, M.M. van den Heuvel-Eibrink, C.Terhaard, Co-promotors: J. Drost)
33. January 28, 2023. J. E. van Atteveld, Bone toxicity and accelerated aging due to childhood cancer treatment. UU Utrecht.(Promotors: M.M. van den Heuvel-Eibrink, co-promotor: S.J.C.M.M. Neggers).
34. June 19, 2023. W. van den Boogaard, Nutritional interventions as a means to reduce chemotherapy-induced toxicity in pediatric cancer patients. UU Utrecht (Promotors: M.M. van den Heuvel-Eibrink, J.H.J. Hoeijmakers, co-promotor: W.P.Vermeij).
35. October 19, 2023. E. Verwaaijen. Musculoskeletal vulnerability and physical frailty during and after treatment for childhood cancer”. UU Utrecht, Promotors: M.M. van den Heuvel-Eibrink, R.Pieters, co-promotor: A. Hartman)
36. October 24, 2023. Vincent Pluimakers. Late metabolic consequences of childhood cancer. UU Utrecht (Promotors: M.M. van den Heuvel-Eibrink, co-promotor: S.J.C.M.M. Neggers, G.O.R. Janssens).
37. November 14, 2023, E. Bertrums, The clonal dynamics underlying the genesis and regression of myeloid disorders, Erasmus University, Rotterdam. (Promotors: C.M. Zwaan, M.M. van den Heuvel-Eibrink, co-promotors: R. van Boxtel, B. Goemans)
38. November 30, 2023. AH van Hulst. Towards Beating Dexamethasone-Induced Side Effects in Children with Acute Lymphoblastic Leukemia UU Utrecht (Promotors: M.M. van den Heuvel-Eibrink, M. Grootenhuis, E. van den Akker).

22-12-2023



**Current PhD projects:  
Expected final**

**Co-supervisor**

2024	M. van der Perk, oncofertility and pediatric cancer	A. Bos / A.v.d. Kooi
2024	P. Raymakers-Jansen, AKI in children with cancer	R. van Asperen/M. Lilien/ M.Fiocco
2024	J van Beek, predicting renal tumor (sub-)types by innovative radiology	A. Littooy/R.de Krijger/J Hendriks
2024	R. Diepstraten, identification of serious ototoxicity in children with cancer	A. Hoetink /M. van Grotel
2025	D. de Winter, bone and metabolic sequelae and childhood cancer	S. Neggers/j van Atteveld
2024	A. Groenendijk, relapsed WT	R.R. de Krijger / J. Drost / A. Mavinkurve
2024	M. Fitski, AI for pediatric renal tumors Littooy	M.Wijnen/L vd Steeg/A.
2025	S. Bon, impact of next gen sequencing on parents R. Wouters	M.Grootenhuis /M.Jongmans /
2025	S. van Peer, genetic susceptibility and RT	M. Jongmans / R. Kuiper
2025	E. Huis in t Veld, CIP	F. Amant, M van Gerwen
2025	D. de Winter, bone and metabolic sequelae and childhood	S. Neggers/j van Atteveld
2026	D. Komninos, toxicity and fasting	J. Hoeijmakers/W. Vermeij
2026	M Buser, innovative imagine guided surgery for pediatric renal tumors. Steeg/B vs velden	M Wijnen/L vd
2026	M. Bolier, GHD/MetS in CCS	S.Neggers/A.J. vd Lely
2026	P. Roy, epidemiological aspects of WT	H.v Tinteren
2026	F. Wens, late effects after WT	S.Neggers/GOR Janssens/H v. Tinteren
2027	N.Streefkerk, tinnitus and hearings loss in CCS	A.Meijer/A.Hoetink
2027	M.Ding, AI for RT contouring in WT	G.O.R.Janssens/M.Maspero
€230.000		
2027	A.Mosroor, genetic and ototoxicity and the role of STS	A. Meijer
2027	N. Claesen, OTC and gonadal damage after CC	A. Bos
2027	A.Larsson nutritional intervention and childhood cancer	J. Hoeijmakers/W. Vermeij

22-12-2023





## Grant Allocations

### *Principal investigator/2<sup>nd</sup> budget source<sup>1</sup>/Other external funding<sup>2</sup>*

- MDR expression in hematopoietic stem cells (1992, Dutch Cancer Society (KWF): Research grant for residents in training, (MM. van den Heuvel-Eibrink, P. Sonneveld, B. Löwenberg)
- MDR related clonal evolution in pediatric AML. (1997-1999) Pediatric Sophia Foundation (SSWO 246), MM. van den Heuvel-Eibrink, P. Sonneveld, H. Buller): Research grant for technician (2 years)
- MDR related clonal evolution in pediatric AML (1999), Kroger Society 1999, MM. van den Heuvel-Eibrink, H. Buller) grant for 6 months research for laboratory research, PhD student: MM. van den Heuvel-Eibrink, 80.000 euro
- Protein expression profiling in childhood leukaemia cells (2005-2009), (KIKA foundation), ML. den Boer, R. Pieters, MM. van den Heuvel-Eibrink). Postdoc: M. Luijendijk, 480.000 euro
- Genetic factors involved in MLL-rearranged AML (2005-2010, KOCR foundation and NWO Mosaic, MM van den Heuvel-Eibrink and CM Zwaan), PhD student: B. Balgobind. 180.000 euro
- Genetic factors contributing to myeloid leukaemia in children with Down syndrome (2008-2012), Sophia foundation & KIKA foundation, CM. Zwaan, MM. van den Heuvel-Eibrink, PhD student: M. Blink & Genetic factors contributing to acute lymphoblastic leukaemia in children with Down syndrome (2008-2012), KIKA foundation and Sophia foundation, PhD student: T. Buitenkamp. 1.085.000 euro
- Epigenetic marks as potential targets for therapy in pediatric acute myeloid leukaemia (2009-2013), KIKA foundation, CM. Zwaan, MM. van den Heuvel-Eibrink, Post-doc: A. Danen-van Oorschot. PhD student D. Valerio. 705.000 euro
- Molecular determinants of childhood MDS and JMML (2007-2010), KIKA foundation, MM. van den Heuvel-Eibrink, CM. Zwaan), PhD student: ACH. de Vries, 393.500 euro
- Metabolic syndrome in childhood cancer survivors (2009-2013), KOCR and KIKA foundation, MM van den Heuvel-Eibrink, S. Neggers, PhD student: M. van Waas/K. Blijdorp. 666.038 euro
- The value of TCR Vbeta repertoire analysis and PNH clones in pediatric patients with refractory cytopenia. (2009-2013), KIKA foundation, M.M. van den Heuvel-Eibrink, V. van der Velden, C.M. Zwaan. PhD student: A. Aalbers, KIKA. 487.215 euro
- Identification of genetic biomarkers associated with leukemic progression of pediatric bone marrow failure syndromes and their prognostic significance for childhood and adult AML. Prof Dr I.P. Touw, P. Sonneveld and Dr M.M. van den Heuvel-Eibrink, MRACE, 2012, 255.000 euro.
- Search for novel therapeutic targets in pediatric MLL-rearranged acute myeloid leukaemia with t(6;11). M.M. van den Heuvel-Eibrink, C.M. Zwaan, R. Pieters, Kika 2012. 97.908,88 Euro.
- NUP98 fusions in pediatric AML determine a specific HOX profile, KOCR, 2012, 270.000 Euro.
- Non-Wilms tumors in children, M.M. van den Heuvel-Eibrink, 2012, St. Da-Da, 55.000 euro
- The role of microRNAs in pediatric AML, KIKA 739.500, 2010, PhD J.E. Kuipers, Postdoc A. Danen
- Aberrant signal transduction profiling in pediatric AML. (2010-2014), KIKA foundation, C.M. Zwaan and M.M. van den Heuvel-Eibrink, PhD student: M. Hermkes, 541.173 euro
- Genetic and metabolic profiling of folate metabolism to predict MTX toxicity in pediatric acute lymphoblastic leukaemia: (2010-2011) KIKA. PhD student: M. te Winkel/M. vd. Hoed. 186.904 euro.
- Late effect studies in a national Dutch cancer survivor cohort. (2009-2014), Quality of life foundation, DCOG Steering committee for late effects: L. Kremer, MM. van den Heuvel-Eibrink, H. Caron, C. Ronckers, B. Versluys, D. Bresters, J. Groot-Loonen, E. van Dulmen, W. Dolsma, W. Tissing, F. van Leeuwen. 4.000.000 euro.
- Assessment of late effects of treatment for Hodgkin's lymphoma F.E. van Leeuwen, B.M.P. Aleman, A. Broeks, N.S. Russell, M. Hauptmann, M. Schaapveld, D. de Jong, Dr. L. Wessels, J.P. de Boer, F. Stewart, L.J. van 't Veer, R. Kerkhoven, S. Schagen, C. Loo, W.E.M. Kok, P.J. Lugtenburg, C.C.M. Janus, A.D.G. Krol, M.B. van 't Veer, J.W.W. Coebergh, L.C. Kremer, M.M. van den Heuvel-

<sup>1</sup> Definition second budget source Erasmus MC: NWO, ZonMw, NCI, 1<sup>o</sup> ronde BSIK, KNAW, EU, NIG and HFSP.

<sup>2</sup> Other external funding like industry, government, funds and charities

22-12-2023



- Eibrink, J.M. Zijlstra, J.M.M. Raemaekers, R.W. van der Maazen, O. Visser, A.J. Swerdlow, D. Easton, K. Oeffinger, C. Moskowitz, S. Darby, D. Cutter, L.L. Robison, A. Kesminiene, M.M. Hawkins, Dutch Cancer Society KWF, 2010, 335.000 euro.
- Molecular unraveling of CCSK, MM van den Heuvel-Eibrink, 2012. S Gookens(sKOCR, 180.000 Euro)
  - Long-term risk of second cancers after treatment for childhood cancer: a DCOG-LATER study. Dr. C.M. Ronckers, Dr. W.J.E. Tissing, Prof.dr.ir. F.E. van Leeuwen, Dr. L.C. Kremer, Dr. E. van Dulmen-den Broeder, Dr. M.M. van den Heuvel-Eibrink, Dr. J Groot-Loonen, Dr. D Bresters, Drs. B Versluys, Dr. W Dolsma, Dr. A. Postma, KWF, 2011, 440.000 euro.
  - Adverse health effects of radiotherapy for childhood cancer. Cecile Ronckers, Huib Caron Leontien Kremer, Floor van Leeuwen, Wil Dolsma, Wim Tissing, Marry van den Heuvel-Eibrink, Eline van Dulmen-den Broeder, Coen Rasch, Marcel van Herk, KWF PG grant-UVA 2012-5517 for 6 years. 523.600 euro
  - Endocrine studies in childhood leukaemia and lymphoma (2001-2005), Stichting KOCC, MM. van den Heuvel-Eibrink, S. de Muinck-Keizer, R. Pieters). PhD student: R van Beek, 160.000 euro
  - Identification of new molecular aberrations of MLL-rearranged AML, (2005-2010), KOCC foundation. MM. van den Heuvel-Eibrink, CM. Zwaan. PhD students: E. Coenen/B. Balgobind. 200.000 euro
  - Molecular determinants of osteogenic problems in childhood ALL(2006-2010). KOCC foundation, MM. van den Heuvel-Eibrink, R. Pieters), PhD student: M. te Winkel, 180.000 euro
  - Unraveling the genetic abnormalities underlying acute myeloid leukaemia with normal karyotype(2006-2011), KOCC foundation; CM. Zwaan and MM. van den Heuvel-Eibrink, PhD student: I. Hollink. KOCC 260.000 euro.
  - Genetic variance in Wilms tumor patients. (2008-2012, MM. van den Heuvel-Eibrink, R. Pieters, KOCC foundation, and SSWO). PhD-fellowship project: H. Segers, 300.000 euro
  - Determinants of fertility in childhood cancer patients and survivors (2010-2014). MM. van den Heuvel-Eibrink, J. Laven and R. Pieters, KOCC foundation (0,5 PhD-project, together with the department of gynaecology), PhD student: W. van Dorp, 117.000 euro.
  - Fitness in short and longterm follow-up after childhood cancer treatment. (2010-2012), KOCC foundation. MM. van den Heuvel-Eibrink, A. Hartman, R. Pieters. Post-doc project: A. Hartman. 100.000 euro.
  - Late effects after childhood cancer. (2011-2013) KOCC foundation. Postdoc: A.C.H. de Vries. 150.000 euro.
  - The identification of novel HOX deregulating mechanisms in pediatric AML (C.M.Zwaan, J.P.P. Meijerink, M.M. van den Heuvel-Eibrink)(2013-2017).KWF: Postdoc: 553.300 Euro.
  - Integration of genomic, epigenomic and proteomic profiling studies in pediatric acute myeloid leukaemia. KiKa PROJECT 109. (M.M. van den Heuvel-Eibrink C.M.Zwaan), Postdoc bio-statistician: 161.500 euro.
  - Medical assessment of adverse health outcomes in Dutch childhood cancer survivors: risk factors, genetic predisposition and screenings tests).MM van den Heuvel-Eibrink, LC Kremer, E van dDulmen-den Broeder, W.J.Tissing) KiKa Programma 171(KiKa EUR 1.341.579 (zegge: een miljoen driehonderd eenenveertig duizend vijfhonderd negenenzeventig euro) and ODAS EUR 627.768
  - Pancare LIFE, a EU-HEALTH FP7 project. (WP leader of the WP4 genetic predisposition of treatment-related gonadotoxicity and ototoxicity) (1.081.000 Euro), and collaborator in WP 2,3,4,5 (on fertility, ototoxicity, associated quality of life studies as well as guideline development)(total project: 6.000.000 Euro).
  - Cooperation of RUNX1 and CSF3R mutations and the role of G-CSF treatment in leukemic transformation of severe congenital; neutropenia, I.Touw and MM van den Heuvel-Eibrink, KIKa, 2014, 193.220 Euro.
  - Characterizing the mutational landscape of pediatric acute myeloid leukaemia without known causative genetic aberration. Dr. M.W.J. Fornerod (PhD), Dr. C.M. Zwaan (MD, PhD), Dr. M.M. van den Heuvel-Eibrink (MD, PhD), (KIKa € 594,271 Euro).
  - Implementation of the DCOG LATER study, LC Kremer, MM van den Heuvel-Eibrink, W.Tissing, E.van Dulmen, 2015 (KIKa-ODAS Foundation, 2.700.000 Euro).

22-12-2023





- CROWN registry in the Princess Máxima Center for Pediatric Oncology (Continuous Registration Of Toxicity in Children with Cancer: a Prospective Warehouse of Determinants). M.M. van den Heuvel-Eibrink, 2017 (Novartis , € 100.000)
- Double blind placebo controlled randomized intervention study to validate the beneficial effect of hydrocortisone on dexamethasone-induced neurobehavioral side effects in pediatric acute lymphoblastic leukemia. M.M. van den Heuvel-Eibrink, E.L.T. van den Akker, M.A. Grootenhuis, [\KIKA](#) project no 268, 2017, bedrag:
- Dr. S.M.F. Pluijm, Dr. S.J.C.M.M. Neggers, Prof. dr. M.M. van den Heuvel-Eibrink. Frailty and accelerated aging in adult survivors of childhood cancer, a DCOG LATER study. (KIKa project no 276, 2017€ 600.000).
- The impact of genetic predisposition in pediatric renal cancer: Genotypic and phenotypic characterization, M.M van den Heuvel-Eibrink, M.C.J. Jongmans, R.P. Kuiper. (KIKa project no 278, 2017, € 429.274).
- Identifying the critically ill pediatric cancer patient R.M. Wösten-van Asperen, M. van Grotel, and M.M. van den Heuvel-Eibrink. 2017 (KIKa project no 287, 2017, € 590.547).
- Prof. dr. M.H.W.A. Wijnen, Prof. Dr. M. Van de Heuvel-Eibrink. 3D-visualisation in the surgery of bilateral Wilms tumours. 2017 (KIKa project no 302 € 55.104).
- Towards enhanced radiotherapy planning by using highly conformal target volumes for flank irradiation in children with renal tumors, M.M. van den Heuvel-Eibrink, G.O.R. Janssens, (KIKa project no 328, 2018, € 159.967).
- Folate and methotrexate-polyglutamate levels in red blood cells during Methotrexate treatment in pediatric acute lymphoblastic leukemia: how to overcome folate over-rescue? M.M. van den Heuvel-Eibrink, R. Pieters, S.G. Heil. (KIKa project no 309, 2018, € 62.057).
- Stichting Gaby Olthuis Fonds, Tinnitus gedurende en na kinderkankerbehandeling, M.M. van den Heuvel-Eibrink, A.J.M. Meijer (2018 € 100.000).
- DWI-MRI based personalized tumor discrimination in children with renal tumors. A. Littooi, M.M. van den Heuvel-Eibrink, R.R. de Krijger (KIKa project no 341, 2019, € 408.617).
- Parents understanding, views and experiences, concerning genomic sequencing in a pediatric renal cancer research setting, MM. van en Heuvel-Eibrink, M. Grootenhuis, M. Jongmans (KIKa project no 339, 2018, € 91.854.00).
- Genetic susceptibility of late effects in the DCOG LATER study, KIKARow, 366.000 Euro
- Relapsed pediatric renal tumors clinical outcome and novel applicable models 250.000 Euro KIKa core funding
- Childhealth encouragement prize 150.000 euros, 2019, for nursing research, kidney failure after childhood cancer
- Liquid biopsies for renal tumors, 2020, the circle project, KIKa 397, L. Tygat, J.Drost, M.M. van den Heuvel-Eibrink.
- Reactions and Emotions of families Linked to Exome Sequencing(the REFLECT study), M.Grootenhuis, M.M. van den Heuvel-Eibrink, M.Jongmans, R.Wouters, (Kika 403, € € 375.355).
- CRADLE II study. F.Amant and MM vd Heuvel-Eibrink, KWF 13192 (€ 474.000)
- Merging 8000 kidney tumor patients from SIOP-RTSG historical data bases, Minke's wish. M.M. van den Heuvel-Eibrink, € 50.593,33.
- Germline mitochondrial variations associated with cisplatin-induced hearing loss in children with cancer.KIKa 419, €98.296 M. M. van den Heuvel-Eibrink and A.Meijer.
- The molecular footprint of Wilms tumors with genetic predisposition. 2022, KIKa 439, €124,998.
- Risk of childhood and adolescent cancer among children conceived after assisted reproductive technology; an international pooling study', (KIKa 444, €100.000) M. Spaan, M.M. van den Heuvel-Eibrink, F. van Leeuwen.
- Tinnitus and its Relation with hearing loss, biomarkers, Genetics and Quality of life in childhood cancer survivors (the TRINGQS study), KiKa Project 448, €483,429 M. M. van den Heuvel-Eibrink and A.Meijer.

22-12-2023



- Determinants of very long-term endocrine Sequelae and renal Toxicity After Renal Tumors in childhood (the STAR project). M.M. van den Heuvel-Eibrink, G.O.R. Janssens, S.J.C.M.M. Neggers, adult endocrinologist, 2023, Dr. Ir. H. van Tinteren, Kika Project 463, €278,914
- AI for optimizing contouring in RT planning for pediatric renal tumours, 2023, KITZ-PMC funding) M.M. van den Heuvel-Eibrink, G.O.R. Janssens, M. Maspero, €230.000.
- AI to optimize histological classification of pediatric renal tumors, 2023, R de Krijger, J vd Laak, A Mavinkurve, M.M. van den Heuvel-Eibrink. €499.678.
- Implementation of STS for otoprotection in children with cancer, 2023, Foundation PMC, M.M. van den Heuvel-Eibrink, A. Meijer, €150.000

*Co-investigator/2<sup>nd</sup> budget source/Other external funding*

- Prospective DCOG study of Dexamethasone based treatment in children with ALL (1997-2005)(PI)
- Prospective study on osteogenic complications during and after treatment of pediatric ALL (1997-2011)(PI)
- Member of the DCOG AML-15 protocol committee (2001-2008), AML 02 protocol (2007- 2013) and AML NOPHO DBH protocol (2014-onwards)
- International EWOG-RC study on TCR Vbeta repertoire analysis and PNH clones (2007-2011)(PI)
- DCOG project on late effects in a national cohort of 7000 survivors of childhood cancer (20 projects, PI of 5 projects, i.e. osteogenic late effects, metabolic syndrome(2), radiotherapy effects after Wilms tumor treatment, GH deficiency)
- Fertility problems after cancer treatment, funded by the Department of Gynaecology and Andrology, Erasmus MC. PhD students: S. Lie Fong and N. van Casteren
- Body composition and Ghrelin in survivors of cancer funded by industry, and department of internal medicine, PhD student: K. Blijdorp

22-12-2023



### **Management/coordinating**

- Hosting the International MDS and Bone Marrow Failure Symposium on behalf of the EWOG group in Rotterdam in 2009
- Organising and coordinating the annual education course for 2nd year medical students on Leukaemia and Lymphoma(3 weeks) together with Prof. Dr. P. Sonneveld and Prof. Dr. J. Van Dongen, since 2002
- Organizing the national DCOG Symposium on Late effects in Rotterdam 16 March 2010
- Organising the Annual KOCR symposium for pediatricians, general practitioners and nurses from 2002-2009
- Since 2010: Organising and coordinating the Minor Pediatric Oncology (10 weeks, 3<sup>rd</sup> year students (together with Prof R. Pieters)
- Member of the Organising Committee for the European late effects meeting (ESSLG) which will be hosted in Amsterdam, September 2011
- Management of 2 Research Groups
- Senior mentor in the mentoring Program of the Erasmus MC since 2011
- Head of the late effects outpatient clinic
- Organising the memorial day of the Sophia Children's Hospital since 1999, 2 times a year
- Member of the organising committee for biannual senior Staff Party of the Erasmus MC-Sophia Children's Hospital, since 2003
- Coordinator of the Minor Pediatric Oncology/Hematology since 2009-2013(12 week full time course for third year bachelor Medicine students)
- Member of the Organising Committee for the International EWOG MDS symposium Prague 7-9 November 2012, Aarhus October 2015, Rome September 2017
- Chef de Clinique, PD wards, Man. Dir. LATE effects clinics, 2009 - 2014 Erasmus MC, as of 2016 Prinses Máxima Centrum voor kinderoncologie.
- Member of the local Organising Committee for the European late effects meeting (ESSLG) Amsterdam, 29 and 30 September 2011
- Member of the Organizing Committee for the International bi-annual Childhood Leukaemia (CLS), Prague, 28-29 April 2014
- Scientific Board Annual European Hematology Association Meeting, 2014 - 2017
- Organizing virtual Biology Meeting, September 2020
- Organizing POKER symposium September 2021, Utrecht
- Organizing ototoxicity symposium, September 2021, Utrecht
- Organizing Annual SIOP-RTSG meetings
- Research Seminar Committee, 2015-2023, PMC, Utrecht
- Organizing monthly HARMONICA meetings since 2015.

### **Lecturing**

- Grand rounds, education on the ward for interns, students and residents (including Grote Visite)
- Educationals and lectures during National meetings and symposia (SKION dagen, KOCR symposia, annual meeting of the NvvH, NHG, PAOG, APOG)
- Educationals and lectures international symposia (SIOP, IBFM, Biannual Leukaemia meetings, EWOG meetings, EULAR/ASPHO, SIOP, SIOPe, SIOP-RTSG, ASPHO, CCLSG meetings)
- Presentations in parent and survivor society meetings (VOKK, EWOG, JMML foundation meeting, Beckwith Wiedeman society, Noonan parents society)

### **Further specified:**

- Presentation: renal tumors in infancy, February 2006, SIOP-RTSG meeting, London
- Invited lecture: TCR Vbeta repertoire analysis in children, a valuable tool to discriminate RC and SAA patients?, 4<sup>th</sup> EWOG congress, Freiburg, 2006

22-12-2023



- Invited lecture: TCR Vbeta repertoire analysis in patients with MDS, April 2006, 5<sup>th</sup> bi-annual meeting on childhood leukaemias, Noordwijkerhout
- Meet the expert lecture, SIOP, October 2008, Berlin
- Presentation: Clinical aspects of inherited bone marrow failure syndromes, November 2006, annual EWOG MDS meeting, Rome
- Invited presentation on renal tumors in Beckwith Wiedeman syndrome, May 2007, Annual meeting of the dutch Beckwith Wiedeman parents Society, Utrecht.
- Grand Round, Erasmus MC-Sophia: Renal tumors in children, from infants to adolescents, June 2007, Rotterdam.
- Presentation, Renal tumors in young children, KOCR symposium, June 2007, Rotterdam
- Presentation Feasibility of using endocrine evaluation for predicting sperm yield in pubertal boys before gonadotoxic treatment, SIOP meeting November 2007, Mumbai
- Invited lecture: Transient myeloproliferative syndrome in Down syndrome, National symposium for Down syndrome patients, November 2007, VuMC, Amsterdam
- Presentation :Differential outcome of pediatric MLL-rearranged AML, December 2007, Atlanta, IBFM-intergroup pediatric AML
- Presentation: Flt3-ITD in childhood JMML, JMML foundation meeting, 2007, Atlanta
- Presentation: MRTK in children, December 2007, SIOP-RTSG meeting, Tubingen
- Presentation: MiRNAs in pediatric AML, international working party on pediatric AML, January 2008, Hannover
- Presentation: International evaluation of malignant rhabdoid tumors in children, SIOP-RTSG meeting, April 2008, Milano
- Presentation:Contribution of bi-allelic mutation in Fanconi anemia genes in a cohort of sporadic WT patients, March 2008, Chamonix, biology meeting of the SIOP-RTSG
- Keynote lecture: “JMML, the past, the present and the future”,International EWOG MDS meeting, 22-24 April 2009, Rotterdam
- Presentation: new agents in pediatric MDS, EWOG MDS meeting, May 2009, Frankfurt
- Invited presentation: Dermatofibrosarcoma protuberans, Artsen cursus diagnostiek en Therapie in de kinderdermatologie, June 2009, Rotterdam
- Presentation: Palliative care for children with cancer, KOCR symposium, June 2008, Rotterdam
- NvvH meeting: Lange termijn effecten na kinderkanker, January 2010, Lunteren
- Grand Round SKZ: “Pediatric AML, as heterogeneous as a fruit basket”, March 2010, Rotterdam.
- KOCR symposium: “Care for LATER”, June 2010, Rotterdam
- Invited lecture: “Long term side effects of aggressive therapy lessons from pediatric Oncology”, June 2010, EULAR, Rome
- Invited presentation: Molecular aberrations in pediatric AML, October 2010, IBFM meeting, Antalya, Turkey
- SIOP meeting: Germline genomic variation in the *MTHFR* and *MTRR* genes determines impairment of bone mineral density in pediatric ALL, October 2010, Boston
- SIOP meeting: Overexpression of the *BRE* gene in pediatric acute myeloid leukaemia is associated with t(9;11)(p21;q23) and favourable outcome, October 2010, Boston.
- EWOG MDS meeting: PNH, TCR V beta repertoire analysis and immunophenotyping of MDS RC, January 2011, Rome.
- IBFM meeting: A *novel* prognostic cryptic translocation in pediatric acute myeloid leukaemia, May, 2011, Gdansk.
- IBFM meeting: The relevance of t(8;16) in pediatric acute myeloid leukaemia, May, 2011, Gdansk.
- EHA course, invited lecture, Diagnostics and therapy in JMML and childhood MDS, October 2011, Sorrento.
- EWOG meeting. Vidasa in pediatric MDS and JMML, November 2011, Ghent.
- JMML foundation meeting, Azacitidine in JMML, December 2011, San Diego.
- Invited lecture on Childhood MDS, International Leukaemia Symposium, Santiago, Chile, 21-24 April, 2012.

22-12-2023



- Molecular and clinical characteristics of *MLL* rearranged AML, Invited lecture, Farewell symposium prof Creutzig, Hannover, Germany, 24-25 May 2012.
- Invited lecture on non-Wilms tumors, ENCCA meeting, Rome, Italy, 7-9 June, 2012.
- Invited lecture "The biology of childhood MDS" 6<sup>th</sup> EWOG MDS symposium, Prague, 7-9 November, 2012.
- Invited lecture: Childhood MDS and JMML, national ped. onc. meeting, Bratislava, April 2013
- Invited lecture: Osteonecrosis in childhood ALL, IBFM meeting Kiel, May 2013.
- Clear Cell Sarcoma in Children , SIOP-RTSG meeting, Paris, June 2013
- Osteogenic side effects in childhood cancer, ICCBH meeting, Rotterdam, June 2013,
- Blastemal Type Wilms Tumors, SIOP meeting, October 2013, Hong Kong
- Molecular unravelling of pediatric AML, invited lecture national Belgium Hematology Association meeting, Gent, January 2014
- DCOG meeting, progress in bone marrow failure and MDS, February 2014
- 15 years research in pediatric Oncology, fare well symposium, prof. R. Pieters, Rotterdam, February 2014
- Renal tumors in children, invited lecture, International Kidney Cancer Coalition Conference 3-5 April 2014, Amsterdam
- Molecular unravelling of pediatric AML M7, May 2014 CLS meeting, Prague.
- The value of PNH clones, TCRVbeta skewing and immunophenotype in childhood RCC, EWOG MDS international business meeting, Prague, May 2014.
- Vidasa in children with MDS and JMML, EWOG MDS international business meeting Prague, May 2014.
- Genetic variation of ototoxicity and gonadal damage, Pancare LIFE meeting, Mainz, June 2014.
- Blastemal type Wilms tumour, ASCO, Chicago, June 2014, oral presentation.
- The implementation of the SIOP 2014 protocol, SIOP-RTSG meeting, Wroclaw, Poland, June 2014.
- Type I/II mutations as molecular MRD targets in pediatric AML, IBFM-AML Steering Group for harmonisation of treatment, Rome, October, 2014.
- Very high risk renal tumors of childhood, on behalf of the SIOP RTSG, Toronto, October 2014.
- Lange termijn reflectie van huisartsen na overlijden van een kind met kanker in de thuissituatie, DCOG Shared care dag, Amsterdam, 21 November 2014.
- Genetic susceptibility of toxicity in childhood cancer patients and survivors, PCL meeting June, Mainz, Germany.
- The biology of AML, ECCO meeting, Vienna, 2015, invited lecture
- JARC & ERN PaedCan Meeting: Renal Tumor Study Group (standard Treatment recommendation & relationships with WIC), Brussel, Belgium; January 2019
- Invited lecture: SIOP Abu Dhabi: Pediatric Renal Tumors, Past , Present and Future, April 2019
- Invited lecture: APOC; Wilms and Renal Tumors: current and emerging therapy/trials, Edinburgh, May 2019
- When the chips are down-POKER and Integration of Intensive Care and Pediatric Oncology, Lyon, October 2019
- German childhood Cancer: Genetic determinants of chemotherapy-induced ototoxicity, Mainz, 23/24 January 2020
- SIOP annual meeting (Ottawa--> Virtual): invited lecture: Battle of the continents, treatment of renal pediatric renal tumors, October 2020
- Invited lecture PICU symposium, September 2021, renal toxicity after childhood cancer
- Invited lectures: Renal Tumors: current and emerging therapy/trials, Edinburgh, APOC; May 2022, Leicester, CCLSG, 2023.

### External consultancies

Member of reviewer committee of The German Cancer Aid this is one of Germany's leading non-profit, non-governmental charitable organizations. The goal of this program is to support collaborative

22-12-2023



translational cancer research projects (CP), clinical trials (Phase I/II; T) and a combination of both (CPT) between Comprehensive Cancer Centers funded by the German Cancer Aid and other centers. Evaluation by video conference and hearings. (January 2021-mid April 2021)

### Patient Care

Patient care comprises approximately 50% of my time and consists of consultancy in the Erasmus MC, outpatient care and consultation services. I participate in the two weekly multidisciplinary tumor boards for pediatric solid tumors, where we discuss all new, as well as hospitalized patients for further treatment management.

Since 2019 my primary focus is on renal tumors, which includes also international consultations and second opinions (in children and adults), survivorship and care for offspring of mothers that suffer from cancer in pregnancy (CIP),

I am also Coordinator national CIP outpatient clinic (120 new subjects per year). Expertise national CIP (Cancer in Pregnancy offspring outpatient clinics, Maxima 2018, onwards).

### Scholarships and prizes

During my pediatric training I received a one year scholarship for laboratory research on a project on leukaemia from the Dutch Cancer Society. In 2004, I received the prestigious SIOP- IPSO Award, by the pediatric oncology surgeons society on the paper and oral presentation. "Characteristics and survival of children with a renal tumor in infancy (0-6 months), a collaborative retrospective study of the SIOP, NWTSG, and UK-CCSG during SIOP 2004, Oslo, 16-19 September". I received a poster award in February 2001. "MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia". International acute leukemia IX Meeting, Munchen, Germany.

Further honors by my group are listed below:

- Gerrit Jan Mulder Prijs 2004: Beste keuze onderzoek. L. te Winkel: Osteogene problematiek in kinderen met acute lymfatische leukemie (ALL) behandeld volgens het ALL9 protocol.
- SKZ prize scientific day 2004: The use of an insuflon device for the administration of G-CSF in pediatric cancer patients.
- SIOP Posteraward AMH, and Inhibine B are valuable new markers for gonadal damage after the treatment of HL without radiotherapy SIOP 2005, Vancouver: (PhD student: R.D. van Beek)
- Poster award February 2008. Gene expression profiling in pediatric AML. International acute leukemia XII Meeting, Munchen, Germany (PhD student: B. Balgobind).
- NWO/Mosaic award 2008 Molecular abnormalities in MLL-rearranged AML (B. Balgobind).
- EUR laureate 2008. Molecular abnormalities in MLL-rearranged AML (B. Balgobind)
- SIOP Posteraward. "Parental experiences of pediatric palliative care and long term levels of grief and depression". SIOP 2008, Berlin (A. Darlington & M.M. van den Heuvel-Eibrink)
- SKZ prize scientific day 2008. A randomized trial investigating an exercise program to prevent reduction of bone mineral density and impairment of motor performance during treatment for childhood acute lymphoblastic leukemia (PhDs A. Hartman/ML te Winkel)
- SIOP Posteraward oktober 2009. Cranial irradiation does not result in pituitary-gonadal axis dysfunction in very long-term male survivors of childhood acute lymphoblastic leukemia. SIOP 2009, Sao Paulo. (PhD student: NJ van Casteren)
- SIOP Posteraward oktober 2012. Genetic variation may modify ovarian reserve in female childhood cancer survivors. SIOP 2012, London. (PhD student: W. Van Dorp)
- EWOG Posteraward november 2012. Type I/II. 6<sup>th</sup> international EWOG MDS meeting (EWOG) 2012, Prague. (PhD student: A.C.H. de Vries)
- Molmed Posteraward 2011. NUP98 aberrations in pediatric AML, I. Hollink and J. de Rooij
- Gerrit Jan Mulder Prijs 2013: Beste keuze onderzoek. I.M.M. van der Geest. Aspecten van psychologische zorg bij kinderen met kanker.
- ICCBH award 2013. Oral presentation Bone mineral density determines fracture rate in children with

22-12-2023





- pediatric ALL, a prospective national study, PhD M.te Winkel.
- SIOP 2013, posteraward, Relevance of small PNH clones on treatment outcome, in MDS-RC, PhD A.Aalbers, 45<sup>th</sup> SIOP meeting, Hong Kong
  - SIOP Young Investigators Award, 2014 (M. den Hoed, S. Gooskens)
  - Merith award ASCO, Chicago, 2014, S.Gooskens.
  - Aspiring to excellence: pituitary expert forum meeting, Wenen, 2014 . Childhood-onset vs. adult-onset craniopharyngioma: preliminary results of a long-term sequelae comparison including 99Yttrium brachytherapy and stereotactic radiotherapy-related complications “commended poster award” .(Mark Wijnen)
  - Tom Voute Award 2015, Clinical and molecular characteristics of CCSK (Saskia Gooskens)
  - SIOP Young Investigator Award, 2015 Cape Town (M van Grotel, and E.Clemens)
  - ICCBH award 2015 (M. den Hoed)
  - SIOP Young Investigator Award, 2016, Dublin, Ireland (L.Warris and A.Ooms)
  - SIOP Young Investigator Award, 2017, Washington DC (J Hol)
  - EURAPAG prize 2017, (van Dorp)
  - Travelawards ASH (B. Balgobind 2007,2008,2009),(I. Hollink 2008,2009), A. Danen-van Oorschot (2009), and E. Coenen (2010, 2012), J. Kuipers (2012), EHA (B. Balgobind 2007,2008).Travelaward ASH 2008(T. Buitenkamp), Trustfonds ASH 2009 (T. Buitenkamp), SIOP travel award: Van Walree fonds, Trust fonds (P. de Laat), Trustfonds Late effects meeting Williamsburg USA, 2010 (M. van Waas, W. van Dorp, K. Blijdorp), Renee Vogels Stipendium,2011, NIHgrant (A.Aalbers), Kolff Nierstichting grant (I.Dekkers), Renee Vogels Stipendium, 2012, I.Dekkers. DCS (KWF) travelers grant for Academics, 2013, S. Gooskens and A. Ooms. 2014 ASH travel awards (J. de Rooij, M. den Hoed), KNAW award(M. den Hoed), 2015 ASH travelawards (J. de Rooij, L. Warris, J. Obenauer), 2017 (S. Noort).
  - WKZ price 2018 for best abstract, Jenneke van Atteveld: prediction model for impaired bone mineral density in childhood cancer survivors.
  - Annual price for best poster and pitch 2018 Madeleine van der Perk: fertility counselling and preservation in childhood cancer patients.
  - Annual price of the school for Cancer Stem Cells & Development 2018, Camilla Calandrini: kidney tumor organoids and compound screen development.
  - Egg cellent Change 2018 price, Theramex for Women, for Health, best communication folder/movie M. van der Perk (€ 5.000)
  - SIOP poster award, November 2018, Dosimetric benefit of highly-conformal volumetric modulated arc therapy (vmat) compared to two opposing photon beams (ap-pa) for flank irradiation in pediatric renal tumors
  - SIOP young investigator award October 2019 J. Atteveld Osteonecrosis in children with ALL, the DCOG experience 1997-2005
  - SIOP young investigator award 2020: A. v.d. Kooi. BRSK, Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function
  - EURAPAG prize 2021, A. v.d. Kooi BRSK1, Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function
  - Young investigator Awards 2021, Annual SIOP meeting M van der Perk, J van Atteveld, J Mul, and A. Meijer, Hawaii.
  - NVK annual award, 2021, Jenneke van Atteveld, bone toxicity in children and survivors with cancer
  - ESPR(European Society of Pediatric Radiology). Young researcher award 2021, Justine N. van der Beek, direct correlation of MRI and histopathology, through the use of a 3D printed cutting guide.
  - Dutch Science Prize 2022, Janna Hol, prevalence of(epi-)genetic predisposing factors in a 5 year unselected national Wilms tumor cohort.UK/Dutch Clinical Genetics Societies & Cancer Genetics Group joint meeting 8<sup>th</sup> March 2022.
  - ICCBH, Dublin 2022, 2 New investigator awards 2022 (D de Winter, bone toxicity in CCS and J van Atteveld, frailty and sarcopenia in CCS), and a best poster Award (E Verwaaijen, novel reliable screening method for identifying sarcopenia in children with ALL)

22-12-2023



- PMC retraite, Synergy Award, 2022, W. Bogaert
- ASH Abstract Achievement Awards, 2022. D de Winter, and E Bertrums
- Schweitzgut Award, 2023, E Bertrums, SIOP, 2023, Ottawa, E Bertrums

22-12-2023

A handwritten signature in blue ink, appearing to read 'M.M. van den Heuvel-Eibrink', written over a horizontal line.